Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Phil Greenfield
Artificial intelligence (AI) and machine learning took center stage at this year’s Radiological Society of North America meeting in Chicago, and the pervasiveness of AI tech in new product launches was further emphasized at the RSNA’s expanded AI Showcase exhibit.
The French start-up claims first-in-man success for heart valve “softening” treatment and plans further trials for an EU launch.
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
Data from two late-breaking drug-eluting stent trials, presented on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco, prompted mixed reactions from interventional cardiologists.
You’re an inventor with a great medtech idea that has yet to receive funding and want feedback from unbiased peers and potential investors. Or perhaps you’ve got your first product to a clinical prototype and you can’t seem to raise that essential funding to push into product development. What do you do now?
The number of new medtech products on the Australian market has slowly declined over the six months to March 2013 and looks set to fall further if, as expected, tougher approval requirements are introduced for higher risk products.